Literature DB >> 16425300

Prognostic factors in node-positive carcinoma of the penis.

Durgatosh Pandey1, Vikash Mahajan, R Ravi Kannan.   

Abstract

BACKGROUND: Lymph node metastasis is the most important prognostic factor in patients with carcinoma of the penis. In this article, we have reviewed the outcome of the patients with pathologic node-positive carcinoma of the penis after groin dissection performed at the Cancer Institute (WIA) between 1987 and 1998.
METHODS: The case records of all patients who underwent groin dissection for carcinoma of the penis between 1987 and 1998 were analyzed.
RESULTS: Between 1987 and 1998, 128 patients underwent groin dissections for carcinoma of the penis at Cancer Institute (WIA), Chennai. Out of them, 102 patients had pathologic node-positive disease. The 5-year overall survival (OS) for these patients was 51.1%. Patients with metastasis only to inguinal nodes had a 5-year OS of 64.6% whereas none of the patients with pelvic nodal metastasis survived for 5 years. Among the pathologically node-positive patients, the factors adversely influencing survival on multivariate analysis were bilateral nodal metastases, number of positive inguinal nodes, pelvic nodal metastasis, and extranodal extension.
CONCLUSIONS: Groin dissection is an effective treatment for nodal metastasis from carcinoma of the penis. However, innovative approaches are needed for the subset of patients with dismal outlook. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16425300     DOI: 10.1002/jso.20414

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  47 in total

Review 1.  Contemporary management of patients with penile cancer and lymph node metastasis.

Authors:  Andrew Leone; Gregory J Diorio; Curtis Pettaway; Viraj Master; Philippe E Spiess
Journal:  Nat Rev Urol       Date:  2017-04-11       Impact factor: 14.432

2.  18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.

Authors:  Niels M Graafland; Renato A Valdés Olmos; Hendrik J Teertstra; J Martijn Kerst; Andries M Bergman; Simon Horenblas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-27       Impact factor: 9.236

3.  Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.

Authors:  Lance C Pagliaro; Dallas L Williams; Danai Daliani; Michael B Williams; William Osai; Michael Kincaid; Sijin Wen; Peter F Thall; Curtis A Pettaway
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

4.  Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Suzanne Richter; J Dean Ruether; Lori Wood; Christina Canil; Patricia Moretto; Peter Venner; Joel Gingerich; Urban Emmenegger; Andrea Eisen; Pawel Zalewski; Anthony Joshua; Som Dave Mukherjee; Daniel Heng; Piotr Czaykowski; Denis Soulieres; Norman Blais; Ricardo Rendon; Neil Fleshner; Juanita M Crook; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

5.  Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.

Authors:  Chuangzhong Deng; Zaishang Li; Shengjie Guo; Peng Chen; Xiaofeng Chen; Qianghua Zhou; Jieping Chen; Xingsu Yu; Xiaoliang Wu; Wenjuan Ma; Qiankun Xie; Yunlin Ye; Yonghong Li; Zike Qin; Zhuowei Liu; Ranyi Liu; Zhenfeng Zhang; Kai Yao; Hui Han; Fangjian Zhou
Journal:  Oncoimmunology       Date:  2016-12-22       Impact factor: 8.110

6.  Radiotherapy plus chemotherapy versus chemotherapy alone in penile cancer patients with extracapsular nodal extension after inguinal lymph node surgery: a multi-institutional study.

Authors:  Zai-Shang Li; Xue-Ying Li; Bin Wang; Peng Chen; Xiang Li; Ornellas Antonio Augusto; Zi-Ke Qin; Zhuo-Wei Liu; Yong-Hong Li; Hui Han; Fang-Jian Zhou
Journal:  World J Urol       Date:  2020-04-17       Impact factor: 4.226

7.  Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.

Authors:  Bradley C Carthon; Chaan S Ng; Curtis A Pettaway; Lance C Pagliaro
Journal:  BJU Int       Date:  2014-06       Impact factor: 5.588

Review 8.  How accurate are present risk group assignment tools in penile cancer?

Authors:  Vincenzo Ficarra; G Novara; R Boscolo-Berto; W Artibani; M W Kattan
Journal:  World J Urol       Date:  2008-06-17       Impact factor: 4.226

9.  The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection.

Authors:  Jian-Ye Liu; Yong-Hong Li; Zhi-Ling Zhang; Kai Yao; Yun-Lin Ye; Dan Xie; Hui Han; Zhou-Wei Liu; Zi-Ke Qin; Fang-Jian Zhou
Journal:  World J Urol       Date:  2013-02-28       Impact factor: 4.226

Review 10.  Shortcomings of the current TNM classification for penile carcinoma: time for a change?

Authors:  Joost A P Leijte; Simon Horenblas
Journal:  World J Urol       Date:  2008-08-09       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.